Free Trial

LightWave Acquisition (LWAC) Competitors

$10.21 +0.01 (+0.10%)
Closing price 05/22/2026 10:08 AM Eastern
Extended Trading
$10.21 0.00 (0.00%)
As of 05/22/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LWAC vs. CALT, AVTE, ELYM, NLTX, and CNTN

Should you buy LightWave Acquisition stock or one of its competitors? MarketBeat compares LightWave Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LightWave Acquisition include Calliditas Therapeutics AB (publ) (CALT), Aerovate Therapeutics (AVTE), Eliem Therapeutics (ELYM), Neoleukin Therapeutics (NLTX), and Hillstream Biopharma (CNTN).

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LightWave Acquisition has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
LightWave AcquisitionN/AN/AN/AN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
LightWave Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled LightWave Acquisition'saverage media sentiment score.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
LightWave Acquisition Neutral

LightWave Acquisition has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. LightWave Acquisition's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
LightWave Acquisition N/A N/A N/A

Summary

LightWave Acquisition beats Calliditas Therapeutics AB (publ) on 4 of the 7 factors compared between the two stocks.

How does LightWave Acquisition compare to Aerovate Therapeutics?

LightWave Acquisition (NASDAQ:LWAC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

LightWave Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LightWave AcquisitionN/A N/A N/A
Aerovate Therapeutics N/A -90.19%-77.47%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LightWave AcquisitionN/AN/AN/AN/AN/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LightWave Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, LightWave Acquisition's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company Overall Sentiment
LightWave Acquisition Neutral
Aerovate Therapeutics Neutral

Summary

LightWave Acquisition beats Aerovate Therapeutics on 3 of the 3 factors compared between the two stocks.

How does LightWave Acquisition compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

LightWave Acquisition's return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eliem TherapeuticsN/A -47.03% -45.97%
LightWave Acquisition N/A N/A N/A

In the previous week, Eliem Therapeutics had 1 more articles in the media than LightWave Acquisition. MarketBeat recorded 1 mentions for Eliem Therapeutics and 0 mentions for LightWave Acquisition. Eliem Therapeutics' average media sentiment score of 0.88 beat LightWave Acquisition's score of 0.00 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Eliem Therapeutics Positive
LightWave Acquisition Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A
LightWave AcquisitionN/AN/AN/AN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
LightWave Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Eliem Therapeutics beats LightWave Acquisition on 4 of the 7 factors compared between the two stocks.

How does LightWave Acquisition compare to Neoleukin Therapeutics?

LightWave Acquisition (NASDAQ:LWAC) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LightWave Acquisition's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LightWave AcquisitionN/A N/A N/A
Neoleukin Therapeutics N/A -37.22%-30.91%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LightWave AcquisitionN/AN/AN/AN/AN/A
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LightWave Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, LightWave Acquisition's average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score.

Company Overall Sentiment
LightWave Acquisition Neutral
Neoleukin Therapeutics Neutral

Summary

LightWave Acquisition beats Neoleukin Therapeutics on 3 of the 5 factors compared between the two stocks.

How does LightWave Acquisition compare to Hillstream Biopharma?

LightWave Acquisition (NASDAQ:LWAC) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

LightWave Acquisition's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
LightWave AcquisitionN/A N/A N/A
Hillstream Biopharma N/A -31.50%-24.72%

1.2% of Hillstream Biopharma shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LightWave AcquisitionN/AN/AN/AN/AN/A
Hillstream BiopharmaN/AN/A-$35.92M-$1.15N/A

In the previous week, Hillstream Biopharma had 1 more articles in the media than LightWave Acquisition. MarketBeat recorded 1 mentions for Hillstream Biopharma and 0 mentions for LightWave Acquisition. LightWave Acquisition's average media sentiment score of 0.00 beat Hillstream Biopharma's score of -0.36 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company Overall Sentiment
LightWave Acquisition Neutral
Hillstream Biopharma Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LightWave Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

LightWave Acquisition and Hillstream Biopharma tied by winning 3 of the 6 factors compared between the two stocks.

Get LightWave Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for LWAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LWAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LWAC vs. The Competition

MetricLightWave AcquisitionPharmaceutical Preparations Industry SectorNASDAQ Exchange
Market Cap$306.77M$927.43M$2.84B$12.34B
Dividend YieldN/A4.84%15.26%5.28%
P/E RatioN/A1.4614.4825.66
Price / SalesN/A119.632,330.3386.31
Price / CashN/A20.0755.4756.67
Price / BookN/A7.597.597.14
Net IncomeN/A-$3.64M-$231.25M$335.98M
7 Day Performance0.20%3.01%1.49%4.11%
1 Month Performance0.34%76.62%1.62%2.52%
1 Year PerformanceN/A126.61%18.49%35.04%

LightWave Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LWAC
LightWave Acquisition
N/A$10.21
+0.1%
N/AN/A$306.77MN/AN/AN/A
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60BN/A180
AVTE
Aerovate Therapeutics
N/A$23.36
-3.2%
N/A+215.9%$676.95MN/AN/A20
ELYM
Eliem Therapeutics
N/A$10.80
-4.7%
N/A+832.2%$321.32MN/AN/A9
NLTX
Neoleukin Therapeutics
N/A$29.82
-4.6%
N/A+60.4%$280.25MN/AN/A90

Related Companies and Tools


This page (NASDAQ:LWAC) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners